ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1677029
This article is part of the Research TopicCheckpoint immunotherapy: Reshaping the landscape of gastrointestinal cancer treatment - Volume IIView all 5 articles
Targeting Pin1 to Overcome Immunosuppressive Tumor Microenvironment in MSS Colorectal Cancer
Provisionally accepted- 1The Jiang Jin Central Hospital of Chongqing, Chongqing, China
- 2Children's Hospital of Chongqing Medical University, Chongqing, China
- 3Chongqing University Fuling Hospital, Chongqing, China
- 4Jiangjin Central Hospital of Chongqing, Chongqing, China
- 5Chongqing Medical University, Chongqing, China
- 6Chongqing University, Chongqing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Management of the immunosuppressive tumor microenvironment (TME) is crucial for microsatellite stability (MSS) colorectal cancer (CRC), which responds poorly to immunotherapy. PIN1, a peptidyl-prolyl cis-trans isomerase that is overexpressed in human malignancies, regulates TME immunosuppression. However, its role in MSS CRC remains insufficiently explored. Methods: We divided 411 CRC patients from the TCGA-COAD database into MSS or microsatellite instability-high (MSI-H) groups and analysed their gene expression profiles. Using smoothed t-statistic SVM, weighted correlation network analysis, and sample clustering, we identified PIN1 as a key biomarker. We assessed Pin1 expression in CRC cell lines and tissues, and conducted functional assays, in vitro co-cultures, and in vivo studies (using a Pin1 inhibitor and anti-PD-1 in CT26 subcutaneous tumor and liver metastasis mouse models) to evaluate its effects and mechanisms. Results: PIN1 was overexpressed in MSS CRC and negatively correlated with CD4+ T and CD8+ T cell infiltration. Knockdown of PIN1 in MSS CRC cells significantly reduced cell proliferation (assessed by CCK-8 assay), impaired migratory capacity (assessed via wound-healing assay), and increased the apoptotic rate (detected by flow cytometry). In CT26 mouse models, combining Pin1 inhibition with PD-1 blockade enhanced immunotherapy efficacy by reducing Treg infiltration, suppressing cancer-associated fibroblast (CAF) activity, and promoting CD8+ T cell recruitment. Mechanistically, PIN1 activated the NF-κB pathway and modulated CCL3-CCR5 signaling, which are critical for Treg migration and CAF activation. Conclusion: Our findings suggest that Pin1 reshapes the immunosuppressive TME in MSS CRC through the NF-κB-CCL3-CCR5 axis, driving CRC progression and immunotherapy resistance. This pathway presents a potential target for overcoming immunotherapy resistance in MSS CRC.
Keywords: Pin1, MSS colorectal cancer (CRC), immunosuppressive tumor microenvironment (TME), Immunotherapy resistance, NF-κB-CCL3-CCR5 axis
Received: 31 Jul 2025; Accepted: 16 Oct 2025.
Copyright: © 2025 Wang, Tang, Fan, Xiao, Wang, Xiang, Liu, Liu, Pei, Jiang, Shuai, Liu, Ye, Xu, Qian, Cui, Xiang and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Siqian Cui, cuisq742278@163.com
Debing Xiang, xdb86@cqu.edu.cn
Chunrong Wu, cqwcr6688@cqu.edu.cn
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.